Antithrombotic Therapy in Children

Michelson, Alan D.; Bovill, E G; Andrew, Maureen

doi:10.1378/chest.108.4_supplement.506s

Cited by 78 publications

(32 citation statements)

References 222 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11,14,35,36 The change most notable in the 2001 ACCP consensus statement was the introduction of LMWH to the pediatric specialist both as a short-term treatment and for long-term treatment in some cases. 14 Long-term treatment and for at least 3 months has been a constant recommendation.…”

Section: Discussionmentioning

confidence: 99%

Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: An increasing population at risk

Sandoval

Sheehan

Stonerock

et al. 2008

Journal of Vascular Surgery

150

104

View full text Add to dashboard Cite

The incidence of DVT in hospitalized children is increasing. Those presenting with DVT typically have prior DVT, thrombophilia, or lower extremity disease. Our study suggests that children admitted with severe medical conditions who require a prolonged intensive care unit stay in addition to central venous access (especially via the femoral vein) should be considered candidates for DVT prophylaxis. A clinical probability scoring system alone cannot stratify patients sufficiently to forgo prophylaxis in hopes of a rapid clinical diagnosis. Childhood-specific level 1 trials aimed at determining guidelines for DVT prophylaxis are urgently required.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: An increasing population at risk

Sandoval

Sheehan

Stonerock

et al. 2008

Journal of Vascular Surgery

150

104

View full text Add to dashboard Cite

show abstract

“…The controversy of the role of prophylactic anticoagulation therapy after the Fontan procedure is in part related to the paucity of data comparing the outcomes of patients receiving different types of anticoagulation regimen. Despite suggestions of a prothrombotic tendency in Fontan patients [14][15][16], there were only few reported series in which all or most of the patients receive long-term anticoagulation [18,20]. Indeed, studies comparing the prevalence of thromboembolic events between patients with and without long-term prophylactic warfarin therapy are virtually nonexistent.…”

Section: Discussionmentioning

confidence: 99%

Long-term anticoagulation therapy and thromboembolic complications after the Fontan procedure

Cheung

Chay

Chiu

et al. 2005

International Journal of Cardiology

View full text Add to dashboard Cite

“…The observation that urokinase cannot completely dissolve intraluminal thrombi [27] could explain these results and we evaluated the effect of urokinase given regularly in an effort to prevent intraluminal thrombus formation. We used the recommended dosage for restoring occluded CVCs [28]. Although at this dose no monitoring is needed, we performed a platelet count and a basic coagulation pro® le before the administration of urokinase to rule out cases of severe thrombocytopenia or coagulation disturbances associated with the underlying illness or its treatment.…”

Section: Discussionmentioning

confidence: 99%

Prophylaxis With Urokinase in Pediatric Oncology Patients With Central Venous Catheters

Kalmanti

Germanakis

Stiakaki

et al. 2002

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

This study evaluated the effects of urokinase in the prevention of central venous catheter (CVC)-related complications in children with malignancy. Fifteen patients with 16 CVCs (study group A) received an intraluminal application of urokinase (10,000 IU in each catheter lumen for 4 h) once a week. They were monitored prospectively with quantitative blood cultures and ultrasonography (color Doppler ultrasound of the great veins and echocardiography). The rate of complications was compared with that of 15 children with 19 CVCs without thromboprophylaxis, treated the previous significantly lower incidence of CVC dysfunction year (control group B). The authors found a wer incidence of CVC dysfunction (3/16 versus 13/19), no major thrombosis, fewer CVC-related bacteremias (2/16 versus 8/19), and a higher salvage of CVCs (1/16 versus 5/19 CVC removals due to persistent bacteremia) in the thromboprophylaxis group. Asymptomatic thrombosis rate was also lower (7/16 cases in group A versus 9/11 in group B when sonography was performed). No hemorrhagic complications were noted. Thromboprophylaxis with urokinase seems a safe and effective measure for reducing the rate of CVC-related complications.

show abstract

Antithrombotic Therapy in Children

Abstract: Therapeutic doses of heparin are the amounts of heparin required to achieve the adult therapeutic range based on the activated partial thromboplastin time (APTT). The recommendations for standardizing APTT values to hep

Cited by 78 publications

References 222 publications

Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: An increasing population at risk

Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: An increasing population at risk

Long-term anticoagulation therapy and thromboembolic complications after the Fontan procedure

Prophylaxis With Urokinase in Pediatric Oncology Patients With Central Venous Catheters

Contact Info

Product

Resources

About